Caladrius Biosciences, Inc. (CLBS) is a leading biotherapeutic company developing treatment modes for the regeneration of damaged or wounded tissues. Some of the lead product candidates of the company include XOWNA or CLBS16 which is in Phase 2a study for the therapeutic potential against coronary microvascular dysfunction. HONEDRA is in Phase 2 clinical trials for the treatment of critical limb ischemia. CLBS201 is a cell therapy for treating chronic kidney diseases. OLOGO is used in the treatment of no-option refractory disabling angina.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
The price of CLBS stock during the regular trading on January 5, 2022, was $1.01 with a slight decline of 1.94%. At last check in the premarket on January 6, 2022, the stock was further significantly down by 4.11%.
CLBS: Events and Happenings
On January 04, 2022, CLBS reported that the company’s executive management presented at two investor conferences. the conferences include Virtual Biotech Showcase held from January 10–12 to January 17–19, 2022 and H.C. Wainwright BioConnect Conference held from January 10-13, 2022.
CLBS: Key Financials
On November 04, 2021, CLBS reported its financial results for the three months ended September 30, 2021. Some of the key updates are as follows.
Net Loss per Share
Basic and diluted net loss for third-quarter 2021 was $6.9 million or $0.12 per share as compared to the same period of 2020 when it was $5.3 million or $0.29 per share. The net loss increased over the year.
Total Assets
The total assets of the company for Q3 2021 were $102 million as compared to the same period of 2020 when the assets were $42 million.
CLBS: CEO Comments
Speaking at the occasion, CEO of CLBS David J. Mazzo said that the company optimized its developmental programs during the third quarter of 2021 despite the COVID-19 pandemic challenges. He further added that the current financial figures enabled CLBS to refine and execute the developmental goals along with assessing the strategic development prospects.
On October 04, 2021, CLBS reported that the company’s Executives presented at the following conferences Virtual UK Kidney Week Conference on October 4-7, Advanced Therapies Congress & Expo on October 5-6, Dawson James Securities Small Cap Growth Conference on October 20-21 and The LD Micro Main Event on October 12-14, 2021.
On September 08, 2021, CLBS reported that the company’s Executives presented at the H.C. Wainwright 23rd Annual Global Investment Conference held on September 13-15, 2021.
Conclusion
Although CLBS stock is 13% up the last month, and the company’s announcement of participation in the investor conferences, the current premarket stock of the company is on a declining verge possibly due to an uncertain market atmosphere. Analysts are proposing that the company should make solid investor-oriented strategies to gain momentum in the market.
